FOI Request
- Disclosure ID
- FOI/03426
- Request Date
- November 19, 2019
- Subject
- Juvenile Ideopathic Arthritis
- Description
I would like to understand how patients with juvenile ideopathic arthritis are being treated. So, in the last 6 months, how many patient(s) with juvenile ideopathic arthritis have been treated with:
Humira (adalimumab)
Amgevita (adalimumab)
Imraldi (adalimumab)
Hyrimoz (adalimumab)
Hulio (adalimumab)
Tocilizumab
Abatacept
Enbrel (etanercept)
Erelzi (etanercept)
Benepali (etanercept)
Golimumab
Remicade (infliximab)
Remsima (infliximab)
Inflectra (infliximab)
Flixabi (infliximab)
Canakinumab
Anakinra
- Response
In the last 6 months there have been 0 patients suffering with juvenile idiopathic arthritis treated by our Trust with any of the above treatments.